The FDA has approved Roche's much-anticipated faricimab for two major causes of blindness, setting up a market clash with Bayer and Regeneron's market leading drug Eylea.
Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular inj
There is plenty of evidence that Novartis' ophthalmology drug Beovu can match its rivals when it comes to efficacy, with less frequent dosing, but the big question facing the company is whe
The FDA has started a priority review of Roche's bispecific antibody faricimab for two major causes of blindness, preparing for a market showdown with Bayer and Regeneron's market-leading E
The FDA has started a review of a new implant version of Roche's ranibizumab therapy for wet age-related macular degeneration, that could offer patients with the sight-robbing disorder an a
Understanding complex scientific studies is often a challenge for patients as well as healthcare professionals, but one that may become easier thanks to artificial intelli
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.